日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study

探索伊他替尼联合依帕卡司他或帕沙克利布治疗晚期实体瘤的安全性、对肿瘤微环境的影响及疗效:一项 I 期研究

Aung Naing, John D Powderly, John J Nemunaitis, Jason J Luke, Aaron S Mansfield, Wells A Messersmith, Solmaz Sahebjam, Patricia M LoRusso, Ignacio Garrido-Laguna, Lance Leopold, Ryan Geschwindt, Kai Ding, Michael Smith, Jordan D Berlin2

Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study

Epacadostat 联合 Pembrolizumab 和化疗治疗晚期实体瘤:I/II 期 ECHO-207/KEYNOTE-723 研究结果

John D Powderly, Samuel J Klempner, Aung Naing, Johanna Bendell, Ignacio Garrido-Laguna, Daniel V T Catenacci, Matthew H Taylor, James J Lee, Fred Zheng, Feng Zhou, Xiaohua Gong, Hema Gowda, Gregory L Beatty0

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

腺苷2A受体阻断作为难治性肾细胞癌的免疫疗法

Lawrence Fong ,Andrew Hotson ,John D Powderly ,Mario Sznol ,Rebecca S Heist ,Toni K Choueiri ,Saby George ,Brett G M Hughes ,Matthew D Hellmann ,Dale R Shepard ,Brian I Rini ,Shivaani Kummar ,Amy M Weise ,Matthew J Riese ,Ben Markman ,Leisha A Emens ,Daruka Mahadevan ,Jason J Luke ,Ginna Laport ,Joshua D Brody ,Leonel Hernandez-Aya ,Philip Bonomi ,Jonathan W Goldman ,Lyudmyla Berim ,Daniel J Renouf ,Rachel A Goodwin ,Brian Munneke ,Po Y Ho ,Jessica Hsieh ,Ian McCaffery ,Long Kwei ,Stephen B Willingham ,Richard A Miller

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

癌症患者对抗 PD-L1 抗体 MPDL3280A 反应的预测相关性

Roy S Herbst, Jean-Charles Soria, Marcin Kowanetz, Gregg D Fine, Omid Hamid, Michael S Gordon, Jeffery A Sosman, David F McDermott, John D Powderly, Scott N Gettinger, Holbrook E K Kohrt, Leora Horn, Donald P Lawrence, Sandra Rost, Maya Leabman, Yuanyuan Xiao, Ahmad Mokatrin, Hartmut Koeppen, Priti

Differential drug responses of circulating tumor cells within patient blood

患者血液中循环肿瘤细胞的差异药物反应

Andrew D Hughes, Jocelyn R Marshall, Eric Keller, John D Powderly, Bryan T Greene, Michael R King

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

单药抗程序性死亡-1 (MDX-1106) 治疗难治性实体瘤的 I 期研究:安全性、临床活性、药效学和免疫学相关性

Julie R Brahmer, Charles G Drake, Ira Wollner, John D Powderly, Joel Picus, William H Sharfman, Elizabeth Stankevich, Alice Pons, Theresa M Salay, Tracee L McMiller, Marta M Gilson, Changyu Wang, Mark Selby, Janis M Taube, Robert Anders, Lieping Chen, Alan J Korman, Drew M Pardoll, Israel Lowy, Suza